Ann Lab Med.  2021 Jan;41(1):16-24. 10.3343/alm.2021.41.1.16.

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

• Tamaki N
• Kurosaki M
• Loomba R
• Izumi N

• KMID: 2512730
• DOI: http://doi.org/10.3343/alm.2021.41.1.16

Abstract

An accurate evaluation of liver fibrosis is clinically important in chronic liver diseases. Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serum marker for liver fibrosis. In this review, we discuss the role of M2BPGi in diagnosing liver fibrosis in chronic hepatitis B and C, chronic hepatitis C after sustained virologic response (SVR), and nonalcoholic fatty liver disease (NAFLD). M2BPGi predicts not only liver fibrosis but also the hepatocellular carcinoma (HCC) development and prognosis in patients with chronic hepatitis B and C, chronic hepatitis C after SVR, NAFLD, and other chronic liver diseases. M2BPGi can also be used to evaluate liver function and prognosis in patients with cirrhosis. M2BPGi levels vary depending on the etiology and the presence or absence of treatment. Therefore, the threshold of M2BPGi for diagnosing liver fibrosis and predicting HCC development has to be adjusted according to the background and treatment status.

Keyword

Mac-2 binding protein glycosylation isomer; Liver fibrosis; Threshold; Hepatocellular carcinoma; Chronic hepatitis C; Chronic hepatitis B; Sustained virologic response; Nonalcoholic fatty liver disease

Figure

• 

  Fig. 1 Clinical utility of M2BPGi in chronic liver diseases. The M2BPGi levels increase as the disease progresses from minimal liver fibrosis to decompensated cirrhosis. M2BPGi can be used to assess disease status, such as liver fibrosis, HCC risk, HCC recurrence risk, liver function, and prognosis of chronic liver diseases, with the progression of the disease. Abbreviations: M2BPGi, Mac-2 binding protein glycosylation isomer; HCC, hepatocellular carcinoma.

Reference

1. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002; 36(S1):S152–60.

2. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology. 2002; 36(S1):S161–72.

3. Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol. 2007; 5:1207–1213.e2.

4. Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology. 2014; 60:1920–8.

5. Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, et al. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals. J Viral Hepat. 2019; 26:893–9.

6. Higuchi M, Tamaki N, Kurosaki M, Watakabe K, Osawa L, Wang W, et al. Prediction of hepatocellular carcinoma after sustained virological responses using magnetic resonance elastography. Clin Gastroenterol Hepatol. 2019; 17:2616–8.

7. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008; 48:835–47.

8. Tamaki N, Kurosaki M, Matsuda S, Nakata T, Muraoka M, Suzuki Y, et al. Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients. Hepatol Res. 2014; 44:720–7.

9. Yada N, Tamaki N, Koizumi Y, Hirooka M, Nakashima O, Hiasa Y, et al. Diagnosis of fibrosis and activity by a combined use of strain and shear wave imaging in patients with liver disease. Dig Dis. 2017; 35:515–20.

10. Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut. 2020; 69:1343–52.

11. Ajmera VH, Liu A, Singh S, Yachoa G, Ramey M, Bhargava M, et al. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease. Hepatology. 2020; 71:849–60.

12. Loomba R, Neuschwander-Tetri BA, Sanyal A, Chalasani N, Diehl AM, Terrault N, et al. Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis. Hepatology. 2020; 21:31121.

13. Tamaki N, Koizumi Y, Hirooka M, Yada N, Takada H, Nakashima O, et al. Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. Hepatol Res. 2018; 48:821–8.

14. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43:1317–25.

15. Tamaki N, Kurosaki M, Tanaka K, Suzuki Y, Hoshioka Y, Kato T, et al. Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C. J Viral Hepat. 2013; 20:72–6.

16. Tamaki N, Kurosaki M, Matsuda S, Muraoka M, Yasui Y, Suzuki S, et al. Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. J Gastroenterol. 2014; 49:1495–503.

17. Takahashi Y, Kurosaki M, Tamaki N, Yasui Y, Hosokawa T, Tsuchiya K, et al. Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications. Hepatol Res. 2015; 45:667–75.

18. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019; 156:1264–81.e4.

19. Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013; 3:1065.

20. Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J Gastroenterol. 2018; 53:819–26.

21. Ito K, Murotani K, Nakade Y, Inoue T, Nakao H, Sumida Y, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: a meta-analysis. J Gastroenterol Hepatol. 2017; 32:1922–30.

22. Moon HW, Park M, Hur M, Kim H, Choe WH, Yun YM. Usefulness of enhanced liver fibrosis, glycosylation isomer of Mac-2 binding protein, galectin-3, and soluble suppression of tumorigenicity 2 for assessing liver fibrosis in chronic liver diseases. Ann Lab Med. 2018; 38:331–7.

23. Toshima T, Shirabe K, Ikegami T, Yoshizumi T, Kuno A, Togayachi A, et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J Gastroenterol. 2015; 50:76–84.

24. Baudi I, Inoue T, Tanaka Y. Novel biomarkers of hepatitis B and hepatocellular carcinoma: clinical significance of HBcrAg and M2BPGi. Int J Mol Sci. 2020; 21:949.

25. Yoneda M, Imajo K, Takahashi H, Ogawa Y, Eguchi Y, Sumida Y, et al. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol. 2018; 53:181–96.

26. Yasui Y, Abe T, Kurosaki M, Matsunaga K, Higuchi M, Tamaki N, et al. Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection. Hepatol Res. 2019; 49:33–41.

27. Rosenberg I, Cherayil BJ, Isselbacher KJ, Pillai S. Mac-2-binding glycoproteins. Putative ligands for a cytosolic beta-galactoside lectin. J Biol Chem. 1991; 266:18731–6.

28. Narimatsu H. Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics. Expert Rev Proteomics. 2015; 12:683–93.

29. Kuno A, Sato T, Shimazaki H, Unno S, Saitou K, Kiyohara K, et al. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin Appl. 2013; 7:642–7.

30. Bekki Y, Yoshizumi T, Shimoda S, Itoh S, Harimoto N, Ikegami T, et al. Hepatic stellate cells secreting WFA⁺-M2BP: its role in biological interactions with Kupffer cells. J Gastroenterol Hepatol. 2017; 32:1387–93.

31. Yamasaki K, Tateyama M, Abiru S, Komori A, Nagaoka S, Saeki A, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 2014; 60:1563–70.

32. Tamaki N, Kurosaki M, Kuno A, Korenaga M, Togayachi A, Gotoh M, et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res. 2015; 45:E82–8.

33. Ura K, Furusyo N, Ogawa E, Hayashi T, Mukae H, Shimizu M, et al. Serum WFA(+)-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C. Aliment Pharmacol Ther. 2016; 43:114–24.

34. Huang CI, Huang CF, Yeh ML, Lin YH, Liang PC, Hsieh MH, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients. Kaohsiung J Med Sci. 2017; 33:394–9.

35. Fujita K, Kuroda N, Morishita A, Oura K, Tadokoro T, Nomura T, et al. Fibrosis staging using direct serum biomarkers is influenced by hepatitis activity grading in hepatitis C virus infection. J Clin Med. 2018; 7:267.

36. Inoue T, Tsuzuki Y, Iio E, Shinkai N, Matsunami K, Fujiwara K, et al. Clinical evaluation of hepatocarcinogenesis and outcome using a novel glycobiomarker Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP) in chronic hepatitis C with advanced fibrosis. Jpn J Infect Dis. 2018; 71:177–83.

37. Nakamura M, Kanda T, Jiang X, Haga Y, Takahashi K, Wu S, et al. Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis. PLoS One. 2017; 12:e0177302.

38. Xu H, Kong W, Liu L, Chi X, Wang X, Wu R, et al. Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C. BMC Gastroenterol. 2017; 17:62.

39. Lin YJ, Chang CL, Chen LC, Hu HH, Liu J, Korenaga M, et al. A glycomarker for short-term prediction of hepatocellular carcinoma: a longitudinal study with serial measurements. Clin Transl Gastroenterol. 2018; 9:183.

40. Tsuji K, Kurosaki M, Itakura J, Mori N, Takaki S, Hasebe C, et al. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol. 2018; 53:1142–50.

41. Izumi N, Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, et al. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int. 2018; 12:356–67.

42. Fujii H, Kimura H, Kurosaki M, Hasebe C, Akahane T, Yagisawa H, et al. Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis. Hepatol Res. 2018; 48:746–56.

43. Akahane T, Kurosaki M, Itakura J, Tsuji K, Joko K, Kimura H, et al. Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. Hepatol Res. 2019; 49:264–70.

44. Sato S, Genda T, Ichida T, Amano N, Sato S, Murata A, et al. Prediction of hepatocellular carcinoma development after hepatitis C virus eradication using serum Wisteria floribunda agglutinin-positive Mac-2-Binding protein. Int J Mol Sci. 2016; 17:2143.

45. Nagata H, Nakagawa M, Nishimura-Sakurai Y, Asano Y, Tsunoda T, Miyoshi M, et al. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatol Int. 2016; 10:956–64.

46. Miyaki E, Imamura M, Hiraga N, Murakami E, Kawaoka T, Tsuge M, et al. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res. 2016; 46:758–64.

47. Morio K, Imamura M, Daijo K, Teraoka Y, Honda F, Nakamura Y, et al. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury. J Gastroenterol. 2017; 52:1252–7.

48. Sasaki R, Yamasaki K, Abiru S, Komori A, Nagaoka S, Saeki A, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS One. 2015; 10:e0129053.

49. Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, Tsunoda T, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017; 67:933–9.

50. Yasui Y, Kurosaki M, Komiyama Y, Takada H, Tamaki N, Watakabe K, et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. Hepatol Res. 2018; 48:1131–9.

51. Akuta N, Suzuki F, Sezaki H, Kobayashi M, Fujiyama S, Kawamura Y, et al. Complex association of virus- and host-related factors with hepatocellular carcinoma rate following hepatitis C virus clearance. J Clin Microbiol. 2019; 57:01463–18.

52. Ishii A, Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, et al. Clinical implications of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment-naive chronic hepatitis B. Hepatol Res. 2017; 47:204–15.

53. Ichikawa Y, Joshita S, Umemura T, Shobugawa Y, Usami Y, Shibata S, et al. Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Hepatol Res. 2017; 47:226–33.

54. Yeh ML, Huang CF, Huang CI, Dai CY, Lin IH, Liang PC, et al. Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. PLoS One. 2019; 14:e0220663.

55. Jekarl DW, Choi H, Lee S, Kwon JH, Lee SW, Yu H, et al. Diagnosis of liver fibrosis with Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP) among chronic hepatitis B patients. Ann Lab Med. 2018; 38:348–54.

56. Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clin Transl Gastroenterol. 2018; 9:163.

57. Wei B, Feng S, Chen E, Li D, Wang T, Gou Y, et al. M2BPGi as a potential diagnostic tool of cirrhosis in Chinese patients with hepatitis B virus infection. J Clin Lab Anal. 2018; 32:24.

58. Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, et al. Mac-2 binding protein glycosylation isomer as a hepatocellular carcinoma marker in patients with chronic hepatitis B or C infection. Hepatol Commun. 2019; 3:493–503.

59. Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study. J Viral Hepat. 2016; 23:977–84.

60. Chuaypen N, Chittmittraprap S, Pinjaroen N, Sirichindakul B, Poovorawan Y, Tanaka Y, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein level as a diagnostic marker of hepatitis B virus-related hepatocellular carcinoma. Hepatol Res. 2018; 48:872–81.

61. Cheung KS, Seto WK, Wong DK, Mak LY, Lai CL, Yuen MF. Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. Oncotarget. 2017; 8:47507–17.

62. Liu J, Hu HH, Lee MH, Korenaga M, Jen CL, Batrla-Utermann R, et al. Serum levels of M2BPGi as short-term predictors of hepatocellular carcinoma in untreated chronic hepatitis B patients. Sci Rep. 2017; 7:14352.

63. Kim SU, Heo JY, Kim BK, Park JY, Kim DY, Han KH, et al. Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. Liver Int. 2017; 37:879–87.

64. Mak LY, Ko M, To E, Wong DK, Ma JH, Hui TL, et al. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. J Gastroenterol Hepatol. 2019; 34:1817–23.

65. Kawaguchi K, Honda M, Ohta H, Terashima T, Shimakami T, Arai K, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B. J Gastroenterol. 2018; 53:740–51.

66. Shinkai N, Nojima M, Iio E, Matsunami K, Toyoda H, Murakami S, et al. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues. J Gastroenterol. 2018; 53:883–9.

67. Su TH, Peng CY, Tseng TC, Yang HC, Liu CJ, Liu CH, et al. Serum Mac-2-Binding protein glycosylation isomer at virological remission predicts hepatocellular carcinoma and death in chronic hepatitis B-related cirrhosis. J Infect Dis. 2020; 221:589–97.

68. Heo JY, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, et al. Use of Wisteria floribunda agglutinin-positive human Mac-2 binding protein in assessing risk of hepatocellular carcinoma due to hepatitis B virus. Medicine (Baltimore). 2016; 95:e3328.

69. Mak LY, To WP, Wong DK, Fung J, Liu F, Seto WK, et al. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. World J Gastroenterol. 2019; 25:1398–408.

70. Hsu YC, Jun T, Huang YT, Yeh ML, Lee CL, Ogawa S, et al. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2018; 48:1128–37.

71. Abe M, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K, et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol. 2015; 50:776–84.

72. Ogawa Y, Honda Y, Kessoku T, Tomeno W, Imajo K, Yoneda M, et al. Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2018; 33:1795–803.

73. Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level in non-alcoholic steatohepatitis. Hepatol Res. 2016; 46:1194–202.

74. Atsukawa M, Tsubota A, Okubo T, Arai T, Nakagawa A, Itokawa N, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein more reliably distinguishes liver fibrosis stages in non-alcoholic fatty liver disease than serum Mac-2 binding protein. Hepatol Res. 2018; 48:424–32.

75. Alkhouri N, Johnson C, Adams L, Kitajima S, Tsuruno C, Colpitts TL, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis. PLoS One. 2018; 13:e0202226.

76. Shigefuku R, Takahashi H, Nakano H, Watanabe T, Matsunaga K, Matsumoto N, et al. Correlations of hepatic hemodynamics, liver function, and fibrosis markers in nonalcoholic fatty liver disease: comparison with chronic hepatitis related to hepatitis C virus. Int J Mol Sci. 2016; 17:1545.

77. Ishiba H, Sumida Y, Tanaka S, Yoneda M, Hyogo H, Ono M, et al. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. J Gastroenterol. 2018; 53:1216–24.

78. Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, et al. Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. Sci Rep. 2019; 9:10109.

79. Kawanaka M, Tomiyama Y, Hyogo H, Koda M, Shima T, Tobita H, et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Hepatol Res. 2018; 48:521–8.

80. Kanno M, Kawaguchi K, Honda M, Horii R, Takatori H, Shimakami T, et al. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis. J Gastroenterol. 2019; 54:549–57.

81. Nah EH, Cho S, Kim S, Kim HS, Cho HI. Diagnostic performance of Mac-2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups. J Clin Lab Anal. 2020; e23316.

82. Hanai T, Shiraki M, Ohnishi S, Miyazaki T, Ideta T, Kochi T, et al. Impact of serum glycosylated Wisteria floribunda agglutinin positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol Res. 2015; 45:1083–90.

83. Uojima H, Hidaka H, Tanaka Y, Inoue T, Onoue M, Wada N, et al. Wisteria floribunda agglutinin-positive human Mac-2 binding protein in decompensated cirrhosis. J Gastroenterol Hepatol. 2018; 33:1889–96.

84. Xu WP, Wang ZR, Zou X, Zhao C, Wang R, Shi PM, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein evaluates liver function and predicts prognosis in liver cirrhosis. J Dig Dis. 2018; 19:242–53.

85. Hayashi T, Tamaki N, Kurosaki M, Wang W, Okada M, Higuchi M, et al. Use of the serum Wisteria floribunda agglutinin-positive Mac2 binding protein as a marker of gastroesophageal varices and liver-related events in chronic hepatitis C patients. Diagnostics (Basel). 2020; 10:173.

86. Lin J, Ko CJ, Hung YJ, Lin PY, Lin KH, Hsieh CE, et al. Prognostic role of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein level in early stage hepatocellular carcinoma. Sci Rep. 2020; 10:5651.

87. Imai D, Maeda T, Wang H, Sanefuji K, Kayashima H, Yoshiya S, et al. Elevation of Mac-2 binding protein glycosylation isomer after hepatectomy is associated with post-hepatectomy liver failure, total Pringle time, and renal dysfunction. Ann Gastroenterol Surg. 2019; 3:515–22.

88. Ishii N, Harimoto N, Araki K, Muranushi R, Hoshino K, Hagiwara K, et al. Preoperative Mac-2 binding protein glycosylation isomer level predicts postoperative ascites in patients with hepatic resection for hepatocellular carcinoma. Hepatol Res. 2019; 49:1398–405.

89. Okuda Y, Taura K, Yoshino K, Ikeno Y, Nishio T, Yamamoto G, et al. Usefulness of Mac-2 binding protein glycosylation isomer for prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma. Ann Surg. 2017; 265:1201–8.

90. Eso Y, Takai A, Takahashi K, Ueda Y, Taura K, Marusawa H, et al. Combination of Mac-2 binding protein glycosylation isomer and Up-To-seven criteria as a useful predictor for child-Pugh grade deterioration after transarterial chemoembolization for hepatocellular carcinoma. Cancers (Basel). 2019; 11:405.

91. Totani H, Kusumoto S, Tanaka Y, Suzuki N, Hagiwara S, Kinoshita S, et al. The value of serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker for hepatitis C virus-related complications after systemic chemotherapy. Int J Hematol. 2016; 104:384–91.

92. Fujiyoshi M, Kuno A, Gotoh M, Fukai M, Yokoo H, Kamachi H, et al. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol. 2015; 50:1134–44.

93. Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Korenaga M, et al. Serum WFA+-M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int. 2016; 36:293–301.

94. Kim HS, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, et al. Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection. Clin Mol Hepatol. 2020; 26:33–44.

95. Sung JH, Uojima H, Hidaka H, Tanaka Y, Wada N, Kubota K, et al. Risk factors for loss of skeletal muscle mass in patients with cirrhosis. Hepatol Res. 2019; 49:550–8.

96. Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, et al. Significant correlation between grip strength and m2bpgi in patients with chronic liver Diseases. J Clin Med. 2019; 8:1359.

97. Nishikawa H, Enomoto H, Iwata Y, Hasegawa K, Nakano C, Takata R, et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis. Hepatol Res. 2016; 46:613–21.

98. Migita K, Horai Y, Kozuru H, Koga T, Abiru S, Yamasaki K, et al. Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis. Medicine (Baltimore). 2018; 97:e13450.

99. Umemura T, Joshita S, Sekiguchi T, Usami Y, Shibata S, Kimura T, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol. 2015; 110:857–64.

100. Nishikawa H, Enomoto H, Iwata Y, Hasegawa K, Nakano C, Takata R, et al. Impact of serum Wisteria floribunda agglutinin positive Mac-2-binding protein and serum interferon-gamma-inducible protein-10 in primary biliary cirrhosis. Hepatol Res. 2016; 46:575–83.

101. Ueno T, Kodama T, Noguchi Y, Saka R, Takama Y, Tazuke Y, et al. Clinical implications of serum Mac-2-binding protein (M2BPGi) during regular follow-up of patients with biliary atresia. Pediatr Surg Int. 2018; 34:1065–71.

102. Yamada N, Katano T, Hirata Y, Okada N, Sanada Y, Ihara Y, et al. Serum Mac-2 binding protein glycosylation isomer predicts the activation of hepatic stellate cells after liver transplantation. J Gastroenterol Hepatol. 2019; 34:418–24.

103. Umetsu S, Inui A, Sogo T, Komatsu H, Fujisawa T. Usefulness of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in children with primary sclerosing cholangitis. Hepatol Res. 2018; 48:355–63.

104. Osawa L, Tamaki N, Kurosaki M, Kirino S, Watakabe K, Wang W, et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein but not α-fetoprotein as a long-term hepatocellular carcinoma predictor. Int J Mol Sci. 2020; 21:3640.

105. Uchiyama H, Shirabe K, Bekki Y, Toshima T, Harimoto N, Ikegami T, et al. Peritransplant kinetics of Mac-2-binding protein glycosylation isomer levels in living donor liver transplantation: its implication of posttransplant small-for-size syndrome. Transl Gastroenterol Hepatol. 2019; 4:41.